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Abstract 
Introduction: Many single-center studies and meta-analyses demonstrate that therapeutic hypothermia (TH), in 
which the body temperature is maintained at 32–35°C, exerts significant neuroprotection and attenuates second-
ary intracranial hypertension after traumatic brain injury (TBI). In 2015, two well-designed multi-center, randomized 
controlled trials were published that did not show favorable outcomes with the use of TH in adult patients with TBI 
compared to normothermia treatment (NT). Therefore, we performed an updated meta-analysis to assess the effect of 
TH in adult patients with TBI.
Methods: We reviewed the PubMed, EMbase, Cochrane Central Register of Controlled Trials, China National Knowl-
edge Infrastructure, and Wanfang Databases. We included randomized controlled trials that compared TH and NT in 
adult patients with TBI. Two reviewers assessed the quality of each study and independently collected the data. We 
performed the meta-analysis using the Cochrane Collaboration’s RevMan 5.3 software.
Results: We included 18 trials involving 2177 patients with TBI. There was no significant heterogeneity among 
the studies. TH could not decrease mortality at 3 months post-TBI (RR 0.95; 95 % CI 0.59, 1.55; z = 0.19, P = 0.85) or 
6 months post-TBI (RR 0.96; 95 % CI 0.76, 1.23; z = 0.29, P = 0.77). There were no significant differences in unfavorable 
clinical outcomes when TH was compared to NT at 3 months post-TBI (RR 0.79; 95 % CI 0.56, 1.12; z = 1.31, P = 0.19) 
or 6 months post-TBI (RR 0.80; 95 % CI 0.63, 1.00; z = 1.92, P = 0.05). TH was associated with a significant increase in 
pneumonia (RR 1.51; 95 % CI 1.12, 2.03; z = 2.72, P = 0.006) and cardiovascular complications (RR 1.75; 95% CI 1.14, 
2.70; z = 2.54, P = 0.01).
Conclusions: Therapeutic hypothermia failed to demonstrate a decrease in mortality and unfavorable clinical out-
comes at 3 or 6 months post-TBI. Additionally, TH might increase the risk of developing pneumonia and cardiovascu-
lar complications.
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Background
Traumatic brain injury (TBI) is a major cause of death 
and disability in the younger population and is a great 
economic and social burden in modern society. Recent 
studies showed a 21  % increase in the incidence of TBI 
during the past five years (Andrews et al. 2015). However, 
effective strategies are few for early care of this disease. 
Secondary elevations in intracranial pressure (ICP) are 
frequent in patients with severe TBI and can cause poor 
outcomes. Thus, the Brain Trauma Foundation (BTF) 
guidelines from 2007 suggest maintaining an ICP below 
20–25 mmHg (Brain Trauma Foundation et al. 2007).
Therapeutic hypothermia (TH), also termed target 
temperature management (TTM), is the controlled low-
ering of core body temperature to below 36  °C and is 
currently recommended by many guidelines for hypoxic 
ischemic encephalopathy and cardiac arrest (Michael 
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2013; Crossley et  al. 2014). Many animal and single-
center studies have demonstrated that therapeutic hypo-
thermia, in which the body temperature is maintained 
at 32–35°C, exerts significant neuroprotection and 
attenuates secondary intracranial hypertension after TBI 
(Soukup et  al. 2002; Oddo et  al. 2009; Colbourne et  al. 
2003; Dietrich and Bramlett 2010; Truettner et al. 2011). 
The effects of TH may include a reduction in cerebral 
metabolic rate of oxygen (Soukup et al. 2002) and cere-
bral glucose demand (Soukup et al. 2002; Colbourne et al. 
2003), a reduction in calcium influx into the brain cells 
and the release of excitotoxic amino acids (Dietrich and 
Bramlett 2010), and the inhibition of early molecular cas-
cades and the stress response, thus preventing apoptosis 
(Truettner et al. 2011).
Two recent meta-analyses published in 2014 (Cross-
ley et al. 2014; Li and Yang 2014) showed that TH might 
be effective in reducing death and unfavorable clinical 
outcomes. However, there were also many controver-
sies. Conflicting results and several negative randomized 
controlled trials (Shiozaki et al. 1993; Clifton et al. 1993; 
Marion et al. 1997; Jiang et al. 2000; Clifton et al. 2001; 
Shiozaki et  al. 2001; Yan and Tang 2001; Clifton et  al. 
2011) have occurred. Moreover, concerns about the 
potential increased risk of pneumonia following the 
induction of TH are evident (Sydenham et al. 2009; Woo 
et al. 2014).
In 2015, two well designed multi-center, randomized 
controlled trials were published (the Brain-Hypothermia 
Study, BHYPO trial (Maekawa et al. 2015); the European 
Study of Therapeutic Hypothermia for Intracranial Pres-
sure Reduction after Traumatic Brain Injury, the Euro-
therm3235Trial (Andrews et al. 2015)) that did not show 
favorable outcomes with the use of TH in patients with 
TBI.
In addition, a recent prospective study (Mtaweh et  al. 
2014) indicated that the energy metabolism rate of chil-
dren is lower than that of adults, which might make the 
feasibility and efficacy of TH different for adult patients. 
Therefore, in the present meta-analysis, we aimed to reas-
sess the effect of TH on mortality, unfavorable clinical 
outcomes (defined as death, a persistent vegetative state, 
or severe disability) and complications in adult patients 
with TBI compared to normothermia treatment (NT).
Methods
Data sources and search strategy
We reviewed studies published in the Pubmed, 
EMbase, Cochrane Central Register of Controlled Tri-
als, China National Knowledge Infrastructure and the 
Wanfang databases. To avoid missing trials, we also 
searched the references from relevant articles. The key-
words and MeSH and Emtree terms used in different 
combinations for the searches, with limitations set to 
randomized controlled trials, were “hypothermia”, “tar-
get temperature management”, “moderate hypother-
mia”, “moderate temperature”, “adult”, “traumatic brain 
injur*”, “head injur*”, “brain injuries”[MeSH]; “trau-
matic brain injury”[Emtree]; “moderate hypothermia, 
induced”[MeSH]; and “hypothermia”[MeSH/Emtree]. 
No limits for language, sample size, gender or the loca-
tion of the original study were entered for the search.
Study selection
We determined the publications that were suitable for 
the meta-analysis using selection criteria as follows: 
(1) Randomized controlled trial (RCT); (2) Population: 
hospitalized adult patients with TBI (as in a previous 
study (Crossley et  al. 2014), we defined adult as being 
the legal age for consent in the country where the trial 
was conducted); (3) Comparison between therapeu-
tic hypothermia (32–35°C) and normothermia; and (4) 
Evaluation of mortality or unfavorable clinical outcomes 
at 3 or 6 months post-TBI. Unfavorable clinical outcomes 
included death, persistent vegetative state or severe dis-
ability that was classified by the Glasgow Outcome Scale. 
Additionally, variables were compared as follows: inci-
dence of new pneumonia, cardiovascular complications 
and bleeding complications. All analyses were based on 
previously published studies; thus, ethical approval and 
patient consent were not required.
Data extraction and quality assessment
Two independent reviewers (Rui Zhang and Haiyan Yin) 
screened the titles and abstracts using a structured data 
abstraction form, which resulted in high and satisfactory 
inter-observer agreement. Any disagreement was resolved 
by consensus or by consulting a third author (Jianrui Wei). 
We extracted the authors’ names, title of the article, jour-
nal in which the study was published, country and year 
of the study, methodological variables and clinical out-
comes. The modified Jadad score was used to evaluate the 
quality of the included trials. Two independent review-
ers (Youfeng Zhu and Xiaoling Ye) assessed the bias of 
the included studies according to the methods described 
in the Cochrane Handbook for Systematic Reviews of 
Interventions (Marion et  al. 1993). The parameters were 
assessed as follows: random sequence generation, blind-
ing of participants and personnel, allocation concealment, 
blinding of outcome assessment, incomplete outcome 
data and selective outcome reporting. According to the 
Cochrane Handbook, other sources of bias were related 
to the specific trial design used or the early termination 
of the study due to an extreme baseline imbalance in the 
selected patients. Because of the nature of these trials, the 
blind method could not be implemented.
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Statistical analysis
The Cochrane Collaboration’s Review Manager Software 
5.3 (RevMan 5.3) was used for the meta-analysis. The 
results were obtained by direct extraction or by indirect 
calculation. The risk ratios (RR) and 95  % confidence 
intervals (CI) were calculated for the binary data, and the 
standardized mean differences (SMD) and 95% CI were 
calculated for the continuous data variables. Heteroge-
neity between trials was tested using the Chi square test, 
with P < 0.05 and I2 greater than 50 % indicating signifi-
cant heterogeneity (Mtaweh et  al. 2014). The random 
effects model was used to calculate the outcomes of both 
the binary and continuous variables, regardless of statis-
tical heterogeneity. Forest plots were used to graphically 
display the results. A funnel plot was used to uncover 
potential publication bias.
Results
Figure 1 shows the selection process for the eligible tri-
als. Initially, 3345 records were identified. After removing 
duplicate records, animal studies, case reports, review 
articles, comments, or studies that were not randomized 
controlled trials, 22 studies remained for assessment. 
Three studies were preliminary reports of subsequent 
studies (Liu et  al. 2006; Flynn et  al. 2015; Marion et  al. 
1993) and were excluded to avoid duplication. One study 
did not report the length of the follow-up period and 
incidence of complications, and was excluded (Yan and 
Tang 2001). Finally, 18 studies were included in the pre-
sent meta-analysis (Andrews et  al. 2015; Shiozaki et  al. 
1993; Clifton et al. 1993; Marion et al. 1997; Jiang et al. 
2000; Clifton et al. 2001; Shiozaki et al. 2001; Clifton et al. 
2011; Maekawa et al. 2015; Gal et al. 2002; Zhi et al. 2003; 
Qiu et  al. 2005, 2006, 2007; Hashiguchi et  al. 2003; Lee 
et  al. 2010; Shiozaki et  al. 1999; Zhao et  al. 2011). The 
qualities of the included RCTs are shown in Table 1. 
A total of 2177 patients with TBIs were included in the 
present meta-analysis. Of these cases, 1122 patients were 
randomly assigned to a TH group, and 1055 patients 
were assigned to an NT group. The characteristics and 
basic demographic parameters of all patients are shown 
in Table 2.
Risk of bias in the included studies We used a tool from 
the Cochrane Collaboration to assess the risk of bias for 
each study and presented the details of the results in Fig. 2.
Effects of mortality
All but one of the included studies (Gal et  al. 2002) 
reported the mortality at the end of the follow-up period. 
Due to variations in trial protocol, the length of the long-
term follow-up period usually varied between 3 and 
6 months. Of these included studies, 4 studies reported 
mortality at 3 months after TBI, 10 studies reported mor-
tality at 6  months after TBI, 3 studies reported mortal-
ity at 1 year after TBI, and 1 study reported mortality at 
2 years after TBI; the length of the follow-up period was 
unclear in 1 studies (Lee et al. 2010). We analysed mor-
tality at 3 and 6 months post-TBI.
Mortality at 3 months post‑TBI
For the analysis of mortality at 3 months post-TBI, 4 trials 
involving 300 patients were included. When the results 
of the 4 studies were statistically aggregated, no signifi-
cant heterogeneity was observed (Chi2  =  1.98, df  =  3, 
P =  0.58; I2 =  0  %) among the studies and therapeutic 
hypothermia was not associated with a significant reduc-
tion in mortality (RR 0.95; 95 % CI 0.59, 1.55; z = 0.19, 
P = 0.85, Fig. 3).
Mortality at 6 months post‑TBI
For the analysis of mortality at 6  months post-TBI, 10 
trials involving 1621 patients were included. When the 
results of the 10 studies were statistically aggregated, no 
significant heterogeneity was observed (Chi2  =  15.52, 
df = 8, P = 0.05; I2 = 48 %) among the studies and thera-
peutic hypothermia was not associated with a signifi-
cant reduction in mortality (RR 0.96; 95 % CI 0.76, 1.23; 
z = 0.29, P = 0.77, Fig. 4).
Mortality in trials with a lower risk of bias
For mortality at the final follow-up in trials assessed as 
having a lower risk of bias (modified Jadad score >3), 5 
trials involving 781 patients were included in this sub-
analysis. When the results of the 5 studies were sta-
tistically aggregated, no significant heterogeneity was 
observed (Chi2 = 3.97, df = 4, P = 0.41; I2 = 0 %) among 
the studies and therapeutic hypothermia was not associ-
ated with a significant reduction in mortality (RR 1.22; 
95 % CI 0.97, 1.54; z = 1.69, P = 0.09, Fig. 5).
Effects of unfavorable clinical outcomes
All of the included studies reported unfavorable clini-
cal outcomes at the end of the follow-up period. Due to 
variations in trial protocol, the length of the long-term 
follow-up period usually varied between 3 and 6 months. 
Of these included studies, 4 studies reported unfavora-
ble clinical outcomes at 3  months after TBI, 11 studies 
reported unfavorable clinical outcomes at 6 months after 
TBI, 2 studies reported unfavorable clinical outcomes at 
1 year after TBI, and 1 study reported unfavorable clinical 
outcomes at 2 years after TBI; the length of the follow-up 
period was unclear in 1 study (Lee et al. 2010). We ana-
lysed unfavorable clinical outcomes at 3 and 6  months 
post-TBI.
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Unfavorable clinical outcomes at 3 months post‑TBI
For the analysis of unfavorable clinical outcomes at 
3 months after TBI, 4 trials involving 300 patients were 
included. When the results of the 4 studies were statisti-
cally aggregated, significant heterogeneity was observed 
(Chi2 = 7.09, df = 3, P = 0.07; I2 = 58 %) among the stud-
ies and no significant difference between the TH and 
NT groups was observed (RR 0.79; 95  % CI 0.56, 1.12; 
z = 1.31, P = 0.19, Fig. 6).
Unfavorable clinical outcomes at 6 months post‑TBI
For the analysis of unfavorable clinical outcomes at 
6 months post-TBI, 11 trials involving 1651 patients were 
included. When the results of the 11 studies were statisti-
cally aggregated, significant heterogeneity was observed 
(Chi2 = 44.59, df = 10, P < 0.001; I2 = 78 %) among the 
studies and no significant difference between the TH and 
NT groups was observed (RR 0.80; 95  % CI 0.63, 1.00; 
z = 1.92, P = 0.05, Fig. 7).
Unfavorable clinical outcomes in trials with a lower risk 
of bias
For the analysis of unfavorable clinical outcomes at the 
final follow-up in trials assessed as a lower risk of bias 
(modified Jadad score >3), 5 trials involving 781 patients 
were included in this sub-analysis. When the results 
of the 5 studies were statistically aggregated, signifi-
cant heterogeneity was observed (Chi2 = 16.78, df = 4, 
P = 0.002; I2 = 76 %) among the studies and no signifi-
cant difference was observed between the TH and NT 
groups (RR 0.84; 95 % CI 0.62, 1.15; z = 1.07, P = 0.29, 
Fig. 8).
Pneumonia complications
A total of 13 RCTs were included involving 844 patients 
who reported pneumonia complications. Significant 
heterogeneity was observed (Chi2  =  26.67, df  =  12, 
P = 0.009; I2 = 55 %) among the 13 trials. In the random 
effects model, the TH group was associated with a higher 



























1154 studies were excluded for 
they were case reports, 
reviews, systematic reviews, or 
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not controlled studies




3 studies were preliminary 
reports of subsequent studies.
1 study was lack of sufficient 
data.
Fig. 1 PRISMA flow diagram of the study selection process
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risk of developing pneumonia than the NT group (RR 
1.51; 95 % CI 1.12, 2.03; z = 2.72, P = 0.006, Fig. 9).
Cardiovascular complications
A total of 11 included studies involving 1346 patients 
reported cardiovascular complications. No significant het-
erogeneity was observed (Chi2 = 10.96, df = 10, P = 0.36; 
I2 = 9 %) among the 11 trials. In the random effects model, 
the TH group was associated with a higher risk of develop-
ing cardiovascular complications than the NT group (RR 
1.75; 95 % CI 1.14, 2.70; z = 2.54, P = 0.01, Fig. 10).
Bleeding complications
A total of 3 RCTs were included involving 522 patients 
who reported bleeding complications. No significant het-
erogeneity was observed (Chi2 = 1.95, df = 2, P = 0.38; 
I2 = 0 %) among the 3 trials. In the random effects model, 
no significant difference in bleeding complications 
between the TH and NT groups was observed (RR 1.28; 
95 % CI 0.40, 4.15; z = 0.42, P = 0.68, Fig. 11).
No publication bias was observed based on a visual 
inspection of the funnel plot (Fig. 12).
Discussion
Many previous studies and meta-analyses (Crossley 
et  al. 2014; Li and Yang 2014) have assessed the effect 
of TH compared to NT in TBI patients, and there were 
contradictory results. This meta-analysis involved 18 
studies including 2177 adult patients with TBI (1122 
in the TH group and 1055 in the NT group) to further 
investigate the effectiveness of TH for the treatment of 
TBI.
The two meta-analyses published in 2014 (Crossley 
et al. 2014; Li and Yang 2014) showed that TH might be 
effective in the treatment of TBI, could decrease mortal-
ity and could be associated with a reduction in unfavora-
ble clinical outcomes compared to NT. No significant 
increases were observed in the development of pneumo-
nia complications in TH compared to NT (Crossley et al. 
2014). The results of present study were different from 
previous studies (Crossley et al. 2014; Li and Yang 2014).
The present meta-analysis indicated that TH could 
not decrease the mortality at 3  months post-TBI (RR 
0.95; 95 % CI 0.59, 1.55; z = 0.19, P = 0.85) or the mor-
tality at 6 months post-TBI (RR 0.96; 95 % CI 0.76, 1.23; 
z = 0.29, P = 0.77) in adult patients with TBI. Addition-
ally, There were no significant differences in unfavorable 
clinical outcomes at 3  months post-TBI (RR 0.79; 95  % 
CI 0.56, 1.12; z = 1.31, P = 0.19) or 6 months post-TBI 
(RR 0.80; 95  % CI 0.63, 1.00; z =  1.92, P =  0.05) when 
TH was compared to NT. Furthermore, TH was associ-
ated with a significant increase in pneumonia complica-
tions (RR 1.51; 95 % CI 1.12, 2.03; z =  2.72, P =  0.006) 
and cardiovascular complications (RR 1.75; 95 % CI 1.14, 
Table 1 Quality of included studies
The modified Jadad score was used to evaluate the quality of included trials
References Randomization method Blind method Allocation concealment Withdrawals/dropouts 
(NG/NJ)
Jadad score
Clifton et al. (1993) Method not mentioned Not used Method not mentioned Yes 3
Shiozaki et al. (1993) Method not mentioned Not used Method not mentioned Yes 3
Marion et al. (1997) Block randomization Not used Method not mentioned Yes 4
Shiozaki et al. (1999) Method not mentioned Not used Method not mentioned Yes 3
Jiang et al. (2000) Method not mentioned Not used Method not mentioned Yes 3
Shiozaki et al. (2001) Method not mentioned Not used Method not mentioned Yes 3
Clifton et al. (2001) Method not mentioned Not used Method not mentioned Yes 3
Gal et al. (2002) Method not mentioned Not used Method not mentioned Yes 3
Zhi et al. (2003) Method not mentioned Not used Method not mentioned Yes 3
Hashiguchi et al. (2003) Method not mentioned Not used Method not mentioned Yes 3
Qiu et al. (2005) Method not mentioned Not used Method not mentioned Yes 3
Qiu et al. (2006) Method not mentioned Not used Method not mentioned Yes 3
Qiu et al. (2007) Randomization table Not used Yes Yes 5
Lee et al. (2010) Method not mentioned Not used Method not mentioned Yes 3
Zhao et al. (2011) Method not mentioned Not used Method not mentioned Yes 3
Clifton et al. (2011) Random number generator Not used Yes Yes 5
Andrews et al. (2015) A central internet or telephone 
based randomization service
Not used Yes Yes 5
Maekawa et al. (2015) Computer-generated Randomi-
zation number
Not used Method not mentioned Yes 4
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Table 2 Characteristics and demographic parameters of patients in the included studies






Clifton et al. (1993)
 Hypothermia 24 16–55 Unknown 32–33 6 48 1 °C/4 h
 Normothermia 22 16–60 Unknown
Shiozaki et al. (1993)
 Hypothermia 16 35.3 ± 15.3 6 M, 10 F 34 5–6 >48 >24 h
 Normothermia 17 35.4 ± 12.6 10 M, 7 F
Marion et al. (1997)
 Hypothermia 40 31 ± 12 36 M, 4 F 32–33 Unknown 24 <1 °C/h
 Normothermia 42 35 ± 15 33 M, 9 F
Shiozaki et al. (1999)
 Hypothermia 8 31.4 ± 12.7 8 M, 0 F 33.5–34.5 (intracranial) Unknown 48 1 °C/day
 Normothermia 8 40.3 ± 23.1 5 M, 3 F
Jiang et al. (2000)
 Hypothermia 43 42.2 35 M, 8 F 33–35 15 72–366 1 °C/h
 Normothermia 44 40.6 37 M, 7 F
Clifton et al. (2001)
 Hypothermia 199 31 ± 12 Unknown 33 6 48 0.25 °C/h
 Normothermia 193 32 ± 13 Unknown
Shiozaki et al. (2001)
 Hypothermia 45 35 ± 20 35 M, 10 F 34 Unknown 48 1 °C/24 h
 Normothermia 46 32 ± 17 31 M, 15 F
Gal et al. (2002)
 Hypothermia 15 Unknown Unknown 34 15 72 Unknown
 Normothermia 15 Unknown Unknown
Hashiguchi et al. (2003)
 Hypothermia 9 29 ± 14.9 9 M, 0 F 34 (intracranial) Unknown 48 1 °C/day
 Normothermia 8 39.1 ± 13.2 5 M, 3 F
Zhi et al. (2003)
 Hypothermia 198 43 ± 17 Unknown 32–35 9 62.4 0.25 °C/h
 Normothermia 198 42 ± 19 Unknown
Qiu et al. (2005)
 Hypothermia 43 40 26 M, 17 F 33–35 Unknown 72–120 Unknown
 Normothermia 43 42.3 30 M, 13 F
Qiu et al. (2006)
 Hypothermia 45 40.1 ± 9.8 29 M, 20 F 33–35 Unknown 72 8–20 h
 Normothermia 45 41.8 ± 11.7 30 M, 15 F
Qiu et al. (2007)
 Hypothermia 40 41.3 25 M, 15 F 33–35 4.1 96 10–24 h
 Normothermia 40 40.2 27 M, 13 F
Lee et al. (2010)
 Hypothermia 29 44.0 ± 15.1 17 M, 12F 33–35 Unknown Unknown Unknown
 Normothermia 16 43.5 ± 16.4 10 M, 6 F
Zhao et al. (2011)
 Hypothermia 40 36.9 ± 14.8 29 M, 10 F 32.7 Within 24 72 Unknown
 Normothermia 41 37.5 ± 15.2 30 M, 11 F
Clifton et al. (2011)
 Hypothermia 52 26 Unknown 33–35 1.6 48 0.5 °C/2 h
 Normothermia 45 31 Unknown
Maekawa et al. (2015)
 Hypothermia 98 39 ± 19 69 M, 29 F 32–34 Within 2 ≥72 1 °C/1 day
 Normothermia 50 39 ± 18 34 M, 16 F
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2.70; z = 2.54, P = 0.01). The findings suggesting possible 
harm of hypothermia could be due to a biologic effect of 
hypothermia or due to the harms or benefits of the other 
therapies used differentially in the two groups (Andrews 
et al. 2015). The results of the present study might lead to 
further understanding of TH in adult patients with TBI 
and should be interpreted with great caution.
Furthermore, there are still many debates regarding 
the recent two RCTs. The BHYPO trial was stopped 
early before the scheduled sample size (300 cases) was 
reached because of a concern about a shortage of TBI 
patients (95 cases). The actual sample size was far below 
the intended target, which might produce bias. For the 
Eurotherm3235 trial, there were many more debates. 
Kiwon Lee considered that hypothermia might be help-
ful only in those patients with truly severe TBI (Lee 
2015). Patients in the Eurotherm3235 trial, including all 
TBI patients with ICP greater than 20 mmHg for 5 min 
after stage 1, might not be the right population to sup-
port the value of hypothermia. As a matter of fact, some 
controversial therapies may be effective only in more 
critically ill patients. Therefore, it was not surprising to 
observe that some patients did well no matter what ther-
apy was used. The Eurotherm3235 trial did not compare 
the combination of TH and standard therapy to stand-
ard therapy alone. In the TH group, mannitol and hyper-
tonic saline were not given unless hypothermia failed to 
control ICP, which differed from the practice of many 
other medical centers where TH was used synchro-
nously with standard therapy. In the Eurotherm3235 
trial, hypothermia alone was compared to the combi-
nation of mannitol and hypertonic saline. Additionally, 
many independent variables that might affect the long-
term clinical outcomes, such as nutrition and advanced 
rehabilitation capabilities, that might affect the out-
come rather significantly. Control of these factors was 
difficult after patients were discharged from the hospi-
tal. Additionally, more patients in the NT group of the 
Eurotherm3235 trial, though there was no statistical dif-
ference, had decompressive craniectomies, which might 
decrease intracranial hypertension more effectively and 
influence the outcomes between the TH and NT groups.
Plus–minus values are mean ± SD
M male, F female, T temperature, N number, TH therapeutic hypothermia
Table 2 continued






Andrews et al. (2015)
 Hypothermia 191 37.4 ± 15.4 Unknown 32–35 Unknown >48 1 °C/4 h
 Normothermia 189 36.7 ± 14.9 Unknown
Fig. 2 Risk of bias summary: authors’ judgments of the risk of bias for 
each item in each included study
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Fig. 3 Mortality at 3 months post-TBI between the TH and NT groups
Fig. 4 Mortality at 6 months post-TBI between the TH and NT groups
Fig. 5 Mortality in trials with a lower risk of bias between the TH and NT groups
Fig. 6 Unfavorable clinical outcomes at 3 months post-TBI between the TH and NT groups
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Several limitations were present in our meta-analysis. 
First, the majority of involved RCTs were single-center 
studies that were assessed to have a high risk of bias, 
which might confound the effects of TH. Additional 
high quality and better-designed multi-center studies 
are needed in the future. Second, the starting time and 
duration of TH and the protocol of rewarming were 
different among the involved studies, which increased 
the risk of bias. Third, significant heterogeneities were 
detected among the studies involved in the present 
Fig. 7 Unfavorable clinical outcomes at 6 months post-TBI between the TH and NT groups
Fig. 8 Unfavorable clinical outcomes in trials with a lower risk of bias between the TH and NT groups
Fig. 9 Pneumonia complications between the TH and NT groups
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meta-analysis when we analysed unfavorable clinical 
outcomes at 3 and 6  months post-TBI, which might 
confound the results, as heterogeneity was one of the 
major concerns in the meta-analysis for validity.
Conclusions
Our meta-analysis demonstrated that therapeutic hypo-
thermia failed to decrease mortality and unfavorable 
clinical outcomes at 3  months post-TBI or 6  months 
post-TBI, and might increase the risk of developing 
pneumonia and cardiovascular complications.
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